Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Fisher Asset Management also has stake in Celegene with 22,854 shares....
http://www.nasdaq.com/quotes/institutional-portfolio/fisher-asset-management-llc-14186/increased?page=5
They hold 497,604 shares of KABOOM. http://www.nasdaq.com/quotes/institutional-portfolio/fisher-asset-management-llc-14186/increased?page=13
Go $PMCB!
Realize that... But was reading too much collusion on the board today.
However....I can't wait for this company to KABOOM! Unfortunately I am over in the UK in school now and will miss the conference call. Do you know if they are they going to post a replay online?
Thanks
Well since everyone is cautious about the source of the PR, try going to PharmaCyte's website under Investor Relations. Posting a link below so you can see for yourself. Go $PMCB http://ir.pharmacytebiotech.com/press-releases/detail/129
NEW YORK, NY -- (Marketwired) -- 01/24/17 -- Ten years ago the National Cancer Institute (NCI) recognized the rise in pancreatic cancer deaths and called for the development of better treatments. The NCI encouraged developers to design more clinical trials that don't use the chemotherapy drug gemcitabine as part of their treatment. PharmaCyte Biotech (OTCQB: PMCB) is on the doorstep of doing just that -- developing a treatment that doesn't use gemcitabine, and instead the company has designed a clinical trial that will actually go head to head with gemcitabine.
In that NCI-sponsored "State of the Science" meeting ten years ago, the organization called for "a need to abandon the mindless propagation of the 'gemcitabine vs. gemcitabine + your drug here' design used for over a decade." PharmaCyte will use its advanced, inoperable pancreatic cancer therapy, which consists of the company's signature live-cell encapsulation technology, Cell-in-a-Box®, plus low doses of the FDA-approved chemotherapy drug ifosfamide, in its upcoming clinical trial where it will go head to head with gemcitabine in order to address an unmet medical need.
Eli Lilly's cancer drug Gemzar® or gemcitabine has been the single-agent "gold standard" for the treatment of pancreatic cancer since the FDA approved it back in 1996. It wasn't until the FDA approved Celgene's cancer drug Abraxane® combined with gemcitabine in 2013 that pancreatic cancer patients had a better option than using gemcitabine alone. The unmet medical need that PharmaCyte expects to address in its clinical trial is for those patients who no longer see any benefit from using Abraxane® combined with gemcitabine.
Eli Lilly, Celgene and PharmaCyte all have something in common with their respective pancreatic cancer therapies -- leading pancreatic cancer expert Dr. Daniel Von Hoff of Translational Drug Development (www.td2inc.com). Dr. Von Hoff was involved as the Principal Investigator in the development of both gemcitabine for Eli Lilly, and Abraxane® combined with gemcitabine for Celgene. Both therapies became the "gold standard" for advanced pancreatic cancer upon FDA approval.
Dr. Von Hoff and his firm Translational Drug Development (TD2) will now help PharmaCyte with its pancreatic cancer therapy in an upcoming clinical trial that he helped design along with Dr. Manuel Hidalgo, who is the Chief of the Division of Hematology-Oncology at Harvard Medical School's Beth Israel Deaconess Medical Center and who will serve as the Principal Investigator in PharmaCyte's upcoming clinical trial, and Dr. Matthias Löhr of the Karolinska Institute in Stockholm, Sweden.
Dr. Von Hoff helped to get approval for Celgene's Abraxane-gemcitabine combination fast-tracked by showing the FDA that there is an urgent need for better treatments for advanced pancreatic cancer, and there is a real opportunity that PharmaCyte's therapy could also be fast-tracked if the company can produce data that is similar or better than the data produced in two earlier independent clinical trials using the therapy.
It is interesting to note that in those earlier clinical trials, PharmaCyte's advanced, inoperable pancreatic cancer therapy provided better results than both gemcitabine alone and the Abraxane-gemcitabine combination.
When comparing current median survival time numbers, based upon recent data, we find that gemcitabine offers 6.7 months of median survival time for advanced pancreatic patients, the Abraxane-gemcitabine combination, on the other hand, offers 8.5 months, while PharmaCyte's therapy offers 11 months, albeit using far fewer overall patients.
The results also included a 100% increase for PharmaCyte's therapy in the one-year survival rate as compared to historical data for gemcitabine, while the Abraxane-gemcitabine combination saw a 59% increase in one-year survival rate over gemcitabine alone.
Also, in those earlier clinical trials, the effects of PharmaCyte's therapy on tumor size were measured at 10 and 20 weeks after treatment. And, in those patients that were treated using Cell-in-a-Box® plus low doses of ifosfamide, not a single patient saw any further growth of their tumors during this period. Two of the 14 patients showed a partial response (more than a 50% reduction in tumor size), 12 patients showed stable disease (tumor reduction of 50-125%) and two patients showed a minor response (tumor reduction of 24-50%). In two patients, their inoperable tumors were reduced enough in size and orientation by PharmaCyte's treatment that those tumors became operable.
In PharmaCyte's upcoming clinical trial, patients who are enrolled in the trial must have inoperable pancreatic cancer that has not yet spread from the pancreas where it first started to any other place in the body. These patients must also have tumors that no longer respond to the combination chemotherapy treatment of Abraxane® plus gemcitabine after they've been on that treatment for a period of between 4 and 6 months.
Patients will be randomly distributed into two groups. The patients in Group 1 will receive PharmaCyte's pancreatic cancer therapy; whereas, those patients in Group 2 will receive treatment with gemcitabine alone.
Unlike in the earlier clinical trials where patients received only two doses of ifosfamide, the company's new trial design calls for multiple cycles of ifosfamide to be given to those patients being treated with PharmaCyte's pancreatic cancer therapy. This will continue until the patients' tumors no longer respond to PharmaCyte's therapy or until treatment-related toxicity accumulates to unacceptable levels.
Also, in the upcoming clinical trial, PharmaCyte will have the advantage of using Imaging Endpoints for radiologic imaging. Imaging Endpoints will provide its advances in radiology science to detect, track and confirm that PharmaCyte's therapy is working. The use of radiologic imaging has become an essential component for the assessment of treatment activity in any treatment plan involving solid tumors, especially in pancreas cancer. And with even more imaging opportunities scheduled in the new trial design, the likelihood of detecting tumor shrinkage and other biologic activity is greatly enhanced.
PharmaCyte recently had a pre-IND meeting with the U.S. FDA to discuss the company's clinical trial, its therapy for pancreatic cancer and its trial design. PharmaCyte has announced it will be hosting a shareholder conference call on February 7, 2017, to discuss the meeting it had with the FDA.
About Stock Market Media Group
Stock Market Media Group is a Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, CEO interviews and feature news articles. This article was written based upon publicly available information. Stock Market Media Group was not compensated for the production of this article.
Stock Market Media Group may from time to time include our own opinions about the companies, their business, markets and opportunities in our articles. Any opinions we may offer about any of the companies we write about are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any of the securities we write about are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid, and as a starting point for doing additional independent research. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: www.sec.gov, where you can also find all of PMCB's filings and disclosures. We also recommend, as a general rule, that before investing in any securities you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.
We are not a registered broker, dealer, analyst, or adviser. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications about any of the companies we write about are not a recommendation to buy or sell a security.
In response to the PR portion:
"Analysts and shareholders are requested to submit questions they may have about PharmaCyte’s clinical development program via email to investorrelations@pharmacyte.com. Mr. Waggoner will respond to as many of the questions as possible in the time permitted for the call."
I think we should start pondering questions of what exactly we want to know. Consolidate them and submit one questionnaire on behalf of investorhub PMCB board
thoughts?
Oh and please go $PMCB. Daddy needs some god in his grill.
Damn Bio... you are quick on the draw. Second time I thought I had you. haha great news regardless.
Nice find n3m3sis. I love hearing "PMCB is pre-revenue, but the company is starting to check the right boxes in terms of lining up a chance at future success." I mean, that's why we are all here right? Future success. If they were already successful then getting in would already be too late.
We only have to be right once. This is our once...
Go $PMCB!
I hear you, but at the end of the day BIG PHARM is all about making money. If they can add #CIAB to their inventory, it is just another effective means to make money. Especially if they could cornerstone the market on diabetes. Imagine being the only company that offers this? Drive the competition out of the field leaving the sole survivor free to charge what ever they want for their "miracle drug".
I feel like a kid at Christmas again. I can't wait to see where $PMCB takes us.... KABOOM!
Do you guys/gals think that a buyout would be the best for PharmaCyte? Of course we would all win, but it might be like the old proverb "give a man a fish and you feed him for a day; teach a man to fish and you feed him for a lifetime."
Would we ALL be better suited to enter into like an renewable agreement and get paid (revenue) to let someone produce and sell it in order to continue funding our research for diabetes, KABOOM. And now i'll take my fish please!
I seen yesterday a genomic company entered into one and their stock shot up from $.27 to $1.28 and after-hours up to $1.51. That is going to be us very soon. Go $PMCB
"today announced a licensing agreement with leading Canadian laboratory services provider (company name), which has selected (company name) ICE COLD-PCR (ICP) technology as its mutation enrichment platform for cancer testing.
Thoughts?
I would welcome that dilutive buyout. If they want to trade me 1 share of Celgene ($117 pps) for 10-12 share of my PMCB, as much as I would hate to let her go... DONESKI.... KABOOM... Gold teeth for everyone and a reunion at Pete's private island!
Go $PMCB #CIAB
What the heck happened today. Unfortunately I was in a meeting today and all heck breaks out. Wish I could have picked up more shares but there will be more times to buy.
We are going to be a rollercoaster for the next few months. If you truly believe in PMCB then no worries. Just keep buying more on the dips and hold. However, if you don't believe in it... good luck because this is going to take off like a rocket. Must maintain patience.
And Green... call who ever you want, your a grown azz man. Trust me, you are not the first to call the FDA and will not be the last. In fact, exercising DD when investing is something that more investors should do more of.
Good luck to all of us... We will be rewarded...and if not it is only my life's savings and retirement. so no pressure. What's to lose. ;0)
Go $PMCB
Hey Promise Land... how's the weather over there? Heading into London in two weeks. First time, not sure what to expect. My only real concern is how to monitor PMCB while working in a different time zone.
We'll see... Hold long, hold strong... she will bless us with riches beyond our wildest dreams. Go $PMCB!
Holding steady at $.1354 and volume at 1.327M... hoping for a day in the green. She will hit .14 at close Go $PMCB
Holding steady at $.1354 and volume at 1.327M... hoping for a day in the green. She will hit .14 at close Go $PMCB
Filled my limit this morning at $.1348 and couldn't be happier.... Go PMCB!
Mick my condolences... I couldn't even begin to imagine losing one of my children to PC. I truly believe that CIAB will change the world so families of tomorrow won't have to experience stories like yours. God bless...
Looking back... I wish I had bought so much more in NOV with prices down to $.023 PPS. Don't be six months from now looking back wishing you had bought more with prices at $.135. Get them while you can and lets ride this once in a lifetime trip to the moon. I got my limit order set for $$$$$$ more first thing in the morning.
KABOOM! Go $PMCB.
Good night longs!
Mahalo
I completely agree. We had far less news in 2014 when this thing was popping into $.50 range. If you ask me, we should be around $.50-$.80 by now. I suspect big PHARM/MM are keeping PPS down in order to secure a buyout at a much more reasonable price.
They don't want to this thing to get rolling because when she takes off, and she will, they won't like paying what they have to. With PC and diabetes... $PMCB = #cashcow
Great news = low volume and declining PPS? Confused... Go $PMCB!
Not the first time this long has been confused with the way this stock moves.... haha
Ready to start the ride of a lifetime. KABOOM!
HOT off the press!!!!
LAGUNA HILLS, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will be meeting with the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) on Tuesday, January 17, 2017. The meeting is to discuss numerous aspects of PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, commenting on the meeting said, "We are pleased that PharmaCyte will be starting out the New Year with a meeting with CBER. PharmaCyte has submitted a list of important questions to the FDA that will be essential to the design of our trial and how it is to be conducted. The questions also touch on the need for any additional information to be developed or submitted to the FDA before PharmaCyte files its Investigational New Drug application (IND). We are looking forward to CBER’s responses so that we can continue with our product development of an effective and safe therapy for LAPC.”
PharmaCyte recently submitted questions to the FDA as part of its pre-IND submission package. With answers to these questions and any additional information provided by CBER during the January 17 meeting, PharmaCyte will address any open issues or requests of CBER before preparing its IND. Once the IND is submitted and found to be acceptable to the FDA, PharmaCyte can proceed with its planned clinical trial in LAPC and enroll patients at the selected trial sites throughout the U.S.
PharmaCyte’s clinical trial in patients with LAPC is designed to meet a clear unmet medical need for those whose cancer no longer responds after 4-6 months of treatment with the combination of Abraxane® plus gemcitabine. The trial will be open-label and multi-site in nature - with sites in the U.S. and Europe. Patients with LAPC will be randomized equally into two groups. One group will receive gemcitabine chemotherapy alone, and the other group will receive PharmaCyte’s pancreatic cancer therapy (encapsulated genetically modified live human cells that can activate the cancer prodrug ifosfamide plus low doses of ifosfamide to eliminate side effects from the chemotherapy). In addition to comparing the anticancer activity and safety of the two therapies, a major aspect of the trial will be to determine if, and how well, PharmaCyte’s therapy can shrink inoperable tumors so that they become operable.
About PharmaCyte Biotech
PharmaCyte Biotech a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated cells are implanted as close to the patient’s cancerous tumor as possible. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide comes in contact with the encapsulated cells they act as an artificial liver and activate the chemotherapy drug at the source of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in no side effects.
In addition to developing a novel therapy for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient they will function as a “bio-artificial pancreas” for purposes of insulin production.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend", "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
HOT off the press!!!!
LAGUNA HILLS, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will be meeting with the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) on Tuesday, January 17, 2017. The meeting is to discuss numerous aspects of PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, commenting on the meeting said, "We are pleased that PharmaCyte will be starting out the New Year with a meeting with CBER. PharmaCyte has submitted a list of important questions to the FDA that will be essential to the design of our trial and how it is to be conducted. The questions also touch on the need for any additional information to be developed or submitted to the FDA before PharmaCyte files its Investigational New Drug application (IND). We are looking forward to CBER’s responses so that we can continue with our product development of an effective and safe therapy for LAPC.”
PharmaCyte recently submitted questions to the FDA as part of its pre-IND submission package. With answers to these questions and any additional information provided by CBER during the January 17 meeting, PharmaCyte will address any open issues or requests of CBER before preparing its IND. Once the IND is submitted and found to be acceptable to the FDA, PharmaCyte can proceed with its planned clinical trial in LAPC and enroll patients at the selected trial sites throughout the U.S.
PharmaCyte’s clinical trial in patients with LAPC is designed to meet a clear unmet medical need for those whose cancer no longer responds after 4-6 months of treatment with the combination of Abraxane® plus gemcitabine. The trial will be open-label and multi-site in nature - with sites in the U.S. and Europe. Patients with LAPC will be randomized equally into two groups. One group will receive gemcitabine chemotherapy alone, and the other group will receive PharmaCyte’s pancreatic cancer therapy (encapsulated genetically modified live human cells that can activate the cancer prodrug ifosfamide plus low doses of ifosfamide to eliminate side effects from the chemotherapy). In addition to comparing the anticancer activity and safety of the two therapies, a major aspect of the trial will be to determine if, and how well, PharmaCyte’s therapy can shrink inoperable tumors so that they become operable.
About PharmaCyte Biotech
PharmaCyte Biotech a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated cells are implanted as close to the patient’s cancerous tumor as possible. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide comes in contact with the encapsulated cells they act as an artificial liver and activate the chemotherapy drug at the source of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in no side effects.
In addition to developing a novel therapy for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient they will function as a “bio-artificial pancreas” for purposes of insulin production.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend", "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
Checked on clinicaltrials.gov to see if $PMCB had started recruiting subjects but nothing yet... Holding my breath because when KABOOM hits, it will be to hot to breath. Will need my gold teeth to dissipate that heat... GO PMCB!
https://clinicaltrials.gov/ct2/results?term=PharmaCyte&Search=Search
Low volume this morning but holding strong above $.1515. Go $PMCB
When "KABOOM" hits. I want everyone to reflect for just a second all the times we adjusted our limit orders to eke out a few more hundred or even a thousand more shares by adjusting the price by even two-thousands of a penny. We will look back and laugh as party into the night on PISTOL PETE private island.
Holding strong at $.151 Go $PMCB
God I hope so... I know my % of the company remains the same if it happens; however, I want to see the price rise on it's own with the amount of shares I have and not 5%, 10% or even worse if they wanted to do a reverse split.
Still long ways away. Gotta keep the 25 meter targets in front of us right now.
GO $PMCB
Do you think they would end up doing a reverse split to look at getting listed?
I concur....
Hell yes... $PMCB at $10 a share, can you imagine? With the amount of shares I have times $10, you know what that will get me? At least a fine dinning experience for some authentic Mexican cuisine at Taco Bell and a $hit ton of gold teeth.... I don't know who brought up these gold teeth but man do I love em....
Go $PMCB #CIAB
Gotta STOP order in just incase they push us down a bit today. Great news again. Shorts don't want to get caught empty handed once the news is released. Once trials are underway, no stopping $PMCB.
#goldteethforall
Plus everybody who's anybody knows that statistically speaking 72% of all statistics are made up on the spot. That is unless the statistics are online then it is just under 85%; 84.34% to be exact. One thing I do know... is that $PMCB is going to make me 100% richer than I currently am.
Disclaimer: all statistics shown here are completely inaccurate and have been made up on the spot except for the last one. Go $PMCB!
FDA Pre-IND meeting....
I have read on here that we are looking at 30 days from the time we requested the meeting until we have one with the FDA. However, according to the FDA's guidance package found at insert-text-here We are looking within 60 days. So maybe just a little longer. Maybe can allow a few of us to save some more money before this thing takes off. Go $PMCB! Anyways just wanted to pass this along. Read below or click on the link.
B. Type B Meeting
Type B meetings are as follows:4
• Pre-investigational new drug application (pre-IND) meetings (21 CFR 312.82)
• Certain end-of-phase 1 meetings (21 CFR 312.82)
• End-of-phase 2 and pre-phase 3 meetings (21 CFR 312.47)
• Pre-new drug application/biologics license application meetings (21 CFR 312.47)
Type B meetings should be scheduled to occur within 60 days of FDA receipt of the written
meeting request. If a sponsor or applicant requests a meeting date that is beyond 60 days from
the date of request receipt, we will work with the sponsor or applicant to determine the earliest
agreeable date.
To promote efficient management of formal meetings, the requestor should try to anticipate
future needs and, to the extent practical, combine product development issues into the fewest
possible meetings. Generally, we will not grant more than one of each of the Type B meetings
for each potential application (e.g., investigational new drug application (IND), new drug
application (NDA), biologics license application (BLA)) or combination of closely related
products developed by the same sponsor or applicant (e.g., same active ingredient but different
dosage forms being developed concurrently), but we can do so when it would be beneficial to
hold separate meetings to discuss unrelated issues. It also may be appropriate to conduct more
than one of some of the Type B meetings for concurrent development of a product for unrelated
claims.
A friendly read on Dr. Von Hoff.
http://www.seenamagowitzfoundation.org/dr-daniel-von-hoff/
Dr. Daniel Von Hoff
Dr. Daniel Von Hoff has dedicated his medical life towards discovering a cure of cancer. Especially subduing pancreatic cancer. Marching towards the ultimate achievement, Dr. Von Hoff works tirelessly to create drugs and treatments that extend quality of life. In spite of spending long exhausting days in clinical research, Dr. Von never loses compassionate sight of his patients and their loved ones. He specializes in the toughest of cancer cases where conventional treatments have failed and patients have little hope of surviving.
Many of his colleagues consider Dr. Von Hoff one of the world’s foremost oncologist, medical researcher and cancer scientist. Renowned for his pancreatic cancer research and involvement in the development of more than a half-dozen revolutionary drugs that have extended the lives of countless pancreatic patients. He has led or been an instrumental participant on more than 200 clinical trials during his career.
Does Dr. Von Hoff Ever Sleep?
The American Society of Clinical Oncology has honored Dr. Von Hoff with its most prestigious award in the field of cancer research. He was recently (2014) honored by Hope Funds for Cancer Research with its Award of Excellence in recognition of outstanding achievement in the fields of research, drug development, medicine, patient support and philanthropy. Dr. Daniel Von Hoff has won so many distinguished awards and recognized for so many accomplishments as well as empathy and personal care that he can be described as a “physician on steroids”.
Dr. Daniel Von Hoff is currently Professor of Medicine, Pathology, Molecular and Cellular Biology, Director of the Arizona Health Sciences Center’s Cancer Therapeutics Program, Executive Vice President, Translational Genomics Research Institute (TGen), Director, TGen’s Translational Drug Development Division and Head, Pancreatic Cancer Research Program. He is also Chief Scientific Officer for US Oncology.
Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents now used routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, CPT-11, and others. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies.
Laboratory contributions have been in the area of in-vitro drug sensitivity testing to individualize treatment for the patient. He and his laboratory are now concentrating on discovery of new targets in pancreatic cancer. Dr. Von Hoff has published more than 515 papers, 127 book chapters, and more than 850 abstracts. Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in June 2004 – March 2010.
Dr. Von Hoff is the past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEXTM Oncology, Inc. (recently acquired by Genzyme). He is founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; and, Editor-in-Chief of Molecular Cancer Therapeutics.
Finally holding steady over $.1315; hopefully we can close at $.135 or higher...
Finally holding steady over $.1315; hopefully we can close at $.135 or higher...
I can't agree more... Having been around since the days of NVLX and comfortable paying $.35 a share, and now picking these up on cheap; this is gonna be a life changing opportunity. I am glad to be apart of this ride. I can't wait until it takes off.
Go $PMBC
Sorry TPX I don't think she has her this morning... She does seem stable after 12 minutes of trading we are over 350K trades and haven't dropped down much if any. We just need to hold stead until we get some good news. go $PMCB
Good luck today everyone and Merry Christmas...
Why not us, right? Go @PMCB
This thing needs to hit and hit big... Daddy needs a new grill. #goldteethforall Seriously though I do need a starter solenoid for my Bronco. And albeit only $17. Having an extra cool $1M in the account always helps...
Good luck everyone, why not us right? Go $PMCB
Good news... Things progressing, not sure if this was posted earlier and if so, sorry...
Pharmacyte Biotech Inc (OTCMKTS:PMCB) Progresses With Patients Enrollment Process In Pancreatic Cancer Clinical Trial
Pharmacyte Biotech Inc (OTCMKTS:PMCB) is successfully making progress with its enrollments process in a pivotal clinic trial targeting advanced, inoperable pancreatic cancer. It started with the enrollment after the FDA approved its pre-IND request meeting. A host of oncologists, clinicians and renowned scientists will discuss with the U.S. regulatory agency on the related study and gain valuable insight on Investigational New Drug application. This is a step that comes after the enrollment process step in a clinical study.
What is the progress?
With Pharmacyte Biotech and a team of famous oncologists all set to introduce a clinical trial in the United States as well as Europe, the FDA’s IND step is vital to accomplishing the goal. After the IND procedure runs its course, stockholders need to be prepared for a 6-month hard stop in the reported clinical trial could lead in the way of report to the industry. Believing the past performance recorded in previous Pharmacyte clinical trials, the company is quite close to making a powerful story for people with severe, inoperable pancreatic cancer.
The company’s pancreatic cancer therapy has been awarded the Orphan Drug Designation, so if it can repeat the strong performance of earlier clinical trials, there is a strong chance that it could successfully get the breakthrough therapy status from the FDA.
There are two segments specifically that could drive to this designation, and they are the quality of life and how well Pharmacyte’s treatment can shrink inoperable tumors for making them operable. In earlier studies, the firm’s treatment did enhance the quality of life and presented the capacity to shrink a pancreatic tumor.
Pharmacyte has acknowledged that there is presently an unmet medical requirement in a segment of locally advanced pancreatic cancer. There are patients that no longer get any benefit from taking of the combination of Abraxane® and gemcitabine after almost 4-6 months of treatment.
https://wallstreetpr.com/pharmacyte-biotech-inc-otcmktspmcb-progresses-with-patients-enrollment-process-in-pancreatic-cancer-clinical-trial-37682
Go $PCMB... Why not us this time, right? Let's go...
The two CTOs were:
1. To change the name from the original CTO from NVLX to $PMCB.
2. To revoke the CTO in CA.
this is a good thing. Go $PMCB!
Their loss our gain... Grab'em while you guys can. Seems Christmas sale came early. Just picked up another 18k at .135
Go $PMCB